Gene therapy offers to beat hepatitis B virus by muting its DNA

An experimental therapy called CRMA-1001 is a remarkable development because, instead of targeting the virus directly, it silences the viral DNA; this is promising because current treatments rarely eliminate the DNA, which allows the virus to rebound